Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

Paul J BröckelmannErin A ZagadailovShelby L CormanViktor ChirikovCourtney JohnsonCynthia MacahiligBrian SealMehul R DalalTim Illidge

Published in: European journal of haematology (2017)

The results of this study provide real-world evidence on the feasibility and effectiveness of BV in elderly or frail ASCT-ineligible patients with rrHL in a real-world setting.

Keyphrases

hodgkin lymphoma
stem cells
randomized controlled trial
community dwelling
systematic review
bone marrow
cell therapy
middle aged
lps induced
lipopolysaccharide induced
platelet rich plasma
mesenchymal stem cells
cross sectional
inflammatory response